Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma

Gut

Volumn 53, Issue 8, 2004, Pages 1180-1189

  Reynaert, H ^a,b   Rombouts, K ^b,c   Vandermonde, A ^b   Urbain, D ^a   Kumar, U ^d   Bioulac Sage, P ^e,f   Pinzani, M ^a   Rosenbaum, J ^e   Geerts, A ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF FLORENCE   (Italy)

^d ROYAL VICTORIA HOSPITAL   (Canada)

^e UNIVERSITÉ DE BORDEAUX   (France)

^f University Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; L 779 976; L 796 778; L 797 591; L 803 087; L 817 818; RECEPTOR SUBTYPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER; LIVER CELL CARCINOMA; LIVER CELL CULTURE; LIVER CIRRHOSIS; NICK END LABELING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STELLATE CELL;

APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 3242732020     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.036053     Document Type: Article

References (48)

1. El Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-5.
2. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-19.
3. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98.
4. Reubi JC, Schaer JC, Laissue JA, et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 1996;45:39-41.
5. Kouroumalis E, Skordilis P, Thermos K, et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
6. Reubi JC, Zimmermann A, Jonas S, et al. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766-74.
7. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002;49:1245-50.
8. Samonakis DN, Moschandreas J, Arnaoutis T, et al. Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002;9:903-7.
9. Yuen MF, Poon RT, Lai CL, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:6B7-91.
10. Rabe C, Pilz T, Allgaier HP, et al. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 2002;40:395-400.
11. Raderer M, Hejna MH, Muller C, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000;16:1197-201.
12. Allgaier HP, Becker G, Olschewski M, et al. Octreotide treatment in patients with advanced hepatocellular carcinoma: first results of the randomized placebo-controlled double blind Hector trial. Hepatology 2003;38(suppl 1):760A.
13. Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992;90:642-6.
14. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999;48:77-85.
15. Niki T, Pekny M, Hellemans K, et al. Glass VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells. Hepatology 1999;29:520-7.
16. Reynaert H, Vaeyens F, Qin H, et al. Somatostatin suppresses endothelin-1-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1. Gastroenterology 2001;121:915-30.
17. Rombouts K, Niki T, Wielant A, et al. Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. J Hepatol 2001;34:230-8.
18. Rohrer SP, Birzin ET, Mosley RT, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998;282:737-40.
19. Rohrer SP, Schaeffer JM. Identification and characterization of subtype selective somatostatin receptor agonists. J Physiol (Paris) 2000;94:211-15.
20. Rombouts K, Wielant A, Hellemans K, et al. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 2001;134:224-32.
21. Marra F, Gentilini A, Pinzani M, et al. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology 1997;112:1297-306.
22. Neaud V, Faouzi S, Guirouilh J, et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997;26:1458-66.
23. Talme T, Ivanoff J, Hagglund M, et al. Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3. Clin Exp Immunol 2001;125:71-9.
24. Yamada Y, Post SR, Wang K, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A 1992;89:251-5.
25. Curtis SB, Hewett J, Yakubovitz S, et al. Somatostatin receptor subtype expression and function in human vascular tissue. Am J Physiol Heart Circ Physiol 2000;278:H1815-22.
26. Curtis SB, Chen JC, Winkelaar G, et al. Effect of endothelial and adventitial injury on somatostatin receptor expression. Surgery 2000;127:577-83.
27. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-52.
28. Ferjoux G, Bousquet C, Cordelier P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris 2000;94:205-10.
29. Chou CK, Ho LT, Ting LP, et al. Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin. J Clin Invest 1987;79:175-8.
30. Ren SG, Ezzat S, Melmed S, et al. Somatostatin analog induces insulin-like growth factor binding protein-1 (IGFBP-1) expression in human hepatoma cells. Endocrinology 1992;131:2479-81.
31. Huynh H, Chow PK, Ooi LL, et al. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002;13:115-22.
32. Guillermet J, Saint-Laurent N, Rochaix P, et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci U S A 2003;100:155-60.
33. Sharma K, Patel YC, Srikant CB. Subtype selective induction of p-53-dependent apoptosis but not cell cycle arrest by human somatostatin receptor 3. Mol Endocrinol 1996;10:1688-96.
34. Chen X, Liu Z, Ai Z. Antineoplastic mechanism of octreotide action in human hepatoma. Chin Med J 2001;114:1167-70.
35. Diaconu CC, Szathmari M, Keri G, et al. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232. Br J Cancer 1999;80:1197-203.
36. Buchan AM, Lin CY, Choi J, et al. Somatostatin, acting at receptor subtype 1, inhibits rho activity, the assembly of actin stress fibers, and cell migration. J Biol Chem 2002;277:28431-8.
37. Schmitz AA, Govek EE, Bottner B, et al. Rho GTPases: signaling, migration, and invasion. Exp Cell Res 2000;261:1-12.
38. Genda T, Sakamoto M, Ichida T, et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999;30:1027-36.
39. Itoh K, Yoshioka K, Akedo H, et al. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221-5.
40. Takamura M, Sakamoto M, Genda T, et al. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001;33:577-81.
41. Stuart KA, Riordan SM, Lidder S, et al. Hepatocyte growth factor/scatter factor-induced intracellular signalling. Int J Exp Pathol 2000;81:17-30.
42. Nakanishi K, Fujimoto J, Ueki T, et al. Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis 1999;17:507-14.
43. Faouzi S, Le Bail B, Neaud V, et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol 1999;30:275-84.
44. Theret K, Musso O, Turlin B, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001;34:82-8.
45. Monvoisin A, Neaud V, De Ledinghen V, et al. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol 1999;30:511-18.
46. Albini A, Florio T, Giunciuglio D, et al. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999;13:647-55.
47. Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 1994;203:253-9.
48. Saito K, Inoue S, Saito T, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002;51:100-4.